The headline presentation at the American College of Cardiology annual scientific sessions, being held March 17-19 in Washington, DC, is Amgen Inc.'s FOURIER cardiovascular outcomes trial of its PCSK9 inhibitor Repatha (evolocumab) – and while the overall positive findings were already released, analysts at Datamonitor Healthcare and Biomedtracker explain there are several important implications to be gleaned from the full results.
In their conference planner, Datamonitor and Biomedtracker analysts note that Amgen "already revealed that the trial met its...